Pathophysiology, Classification, and KDIGO-Guided Management
CKD mineral and bone disorder (CKD-MBD) is a systemic disorder of mineral metabolism unique to kidney disease. It encompasses dysregulation of phosphate, calcium, fibroblast growth factor-23 (FGF-23), parathyroid hormone (PTH), and vitamin D, resulting in abnormalities of bone architecture (renal osteodystrophy), vascular calcification, and systemic mineral imbalance. CKD-MBD significantly contributes to cardiovascular mortality and morbidity in CKD and ESRD populations.
CKD-MBD pathophysiology centers on phosphate retention: eGFR decline → reduced phosphate excretion → serum phosphate elevation → FGF-23 rise → secondary PTH elevation → vitamin D suppression. Hyperparathyroidism drives bone loss and vascular calcification. KDIGO targets: keep Ca/P within normal, target PTH to 2–9× normal for stage (varies by KDIGO stage), minimize vascular calcification.
Kidney biopsy and bone biomarkers (PTH, alkaline phosphatase, P1NP) classify renal bone disease.
| Pathology | Increased osteoblast and osteoclast activity; peritrabecular fibrosis |
| Biomarkers | PTH >300 pg/mL (typically), high alkaline phosphatase, elevated P1NP |
| Prevalence | ~70–80% of ESRD patients on dialysis |
| Pathophysiology | SHPT → excessive PTH → bone resorption outpaces formation |
| Clinical Features | Bone pain, proximal weakness, high fracture risk despite high turnover (paradox: increased turnover but poor bone quality) |
| Management | Target phosphate, normalize calcium, PTH suppression with vitamin D ± calcimimetics |
| Pathology | Low bone cell activity; minimal osteoblast/osteoclast function; replacement of bone with woven fibrous tissue |
| Biomarkers | PTH <150 pg/mL (classically), low-normal alkaline phosphatase, low P1NP |
| Prevalence | ~20–30% of ESRD; increasing due to aggressive PTH suppression |
| Pathophysiology | Excessive suppression of PTH (over-treatment with vitamin D/calcimimetics); accumulation of aluminum or strontium |
| Risk Factors | Chronic aluminum exposure (contaminated dialysate, binders), over-aggressive PTH suppression, older age, diabetes |
| Clinical Features | Fracture risk paradoxically high (poor bone formation despite low resorption); slow healing |
| Management | Moderate PTH suppression (target 2–9× normal); avoid excessive vitamin D; remove aluminum; minimize calcimimetics if possible |
| Pathology | Defective mineralization; accumulation of unmineralized osteoid |
| Biomarkers | Low PTH, elevated alkaline phosphatase, elevated osteoid volume on biopsy |
| Pathophysiology | Severe vitamin D deficiency (decreased 1,25(OH)2D); aluminum deposition in bone |
| Clinical Features | Bone pain, muscle weakness, fractures |
| Management | Vitamin D (native or active form); treat aluminum exposure |
| Pathology | Features of both high turnover and low turnover disease; heterogeneous bone changes |
| Biomarkers | Intermediate PTH, variable alkaline phosphatase |
| Prevalence | ~5–10% of ESRD |
| Management | Balance PTH suppression; optimize phosphate and calcium; vitamin D supplementation |
The classic teaching—“high PTH = high turnover, low PTH = low turnover”—is helpful but incomplete. Adynamic bone disease can develop despite PTH suppression if aluminum accumulates or if vitamin D is withheld. Always treat to KDIGO targets and monitor bone marker trends.
Hyperphosphatemia and elevation of the calcium-phosphate product (Ca × P) drive vascular smooth muscle cell phenotypic transition to osteogenic cells, resulting in calcification. Unlike atherosclerotic calcification (intimal), uremic calcification is predominantly medial (vascular wall) and is mediated by loss of natural inhibitors (fetuin-A, pyrophosphate).
Coronary artery calcification score independently predicts cardiovascular death in CKD and ESRD populations.
| Stage | eGFR | PTH | Phosphate | Calcium | Notes |
|---|---|---|---|---|---|
| G3a | 45–59 | Normal × 1–1.5× | Normal | Normal | Avoid chronic hypercalcemia; prevent hyperphosphatemia |
| G3b | 30–44 | Normal × 1.5× | Monitor; restrict if elevated | Monitor | Early intervention: restrict phosphate diet, consider binders |
| G4 | 15–29 | Normal × 1.5–3× | Aim <4.6 mg/dL | 8.5–10 mg/dL | Restrict phosphate; start vitamin D if deficient; assess for hyperparathyroidism |
| G5D | <15 | Normal × 2–9× | 3.5–5.5 mg/dL | 8.5–10 mg/dL | Intensive management: multiple modalities; individualize targets |
Avoid rapid, aggressive changes in mineral parameters. Overcorrection (excessive PTH suppression, hypercalcemia) risks adynamic bone disease and calcification. The goal is gradual normalization of phosphate and calcium, with PTH maintained in a physiologic range.
Used when dietary restriction alone is inadequate (typically when serum P >4.5 mg/dL in G4–G5).
| Binder Class | Agent | Mechanism | Advantages | Disadvantages |
|---|---|---|---|---|
| Calcium-based | Calcium carbonate, calcium acetate | Binds PO4 in gut; increases Ca absorption | Inexpensive; improves Ca balance | Risk of hypercalcemia; promotes vascular calcification if used excessively |
| Non-calcium | Sevelamer HCl, sevelamer carbonate | Polymer binds phosphate | No hypercalcemia risk; may lower cholesterol | GI side effects; large pill burden |
| Lanthanum carbonate | Lanthanum | Rare earth binds phosphate | Effective; reasonable pill burden | Minimal long-term safety data; rare GI toxicity |
| Iron-based | Sucroferric oxyhydroxide, ferric citrate | Iron core binds phosphate | Effective; may improve iron status (ferric citrate) | GI upset possible; dark stool |
| Magnesium-based | Magnesium carbonate | Magnesium + carbonate binds phosphate | Avoids Ca/Al excess | Hypermagnesemia risk (usually offset by dialysis) |
“Restrict dose of calcium-based binders; calcium-free binders may favor halting progression of vascular calcification compared with calcium-containing binders.”
| Type | Agent | Indication | Advantages | Disadvantages |
|---|---|---|---|---|
| Native | Cholecalciferol (D3) | CKD G3–G4 with low 25(OH)D | Safe; physiologic; inexpensive | Slow onset; may not be adequate in G4 with very low 1,25(OH)2D |
| Active | Calcitriol, paricalcitol, doxercalciferol | CKD G4–G5D with SHPT | Rapid PTH suppression; improves Ca/P balance | Risk of hypercalcemia; need monitoring; expensive |
| Calcimimetic | Cinacalcet, etelcalcetide | SHPT refractory to vitamin D | Suppress PTH directly; no hypercalcemia risk; may reduce need for parathyroidectomy | Nausea, vomiting; risk of hypocalcemia; expensive |
Post-parathyroidectomy, monitor Cr, calcium, phosphate. Administer IV calcium + dextrose to prevent “hungry bone syndrome” (acute hypocalcemia from rapid bone healing).
Not routinely recommended; consider if:
| Marker | Interpretation | Use |
|---|---|---|
| PTH (intact) | High → high turnover; low → low turnover | Primary screening; KDIGO targets |
| Alkaline phosphatase (ALP) | Elevated with high turnover; normal/low with low turnover | Adjunctive; supports PTH findings |
| Bone-specific ALP | More specific for bone than total ALP | Less used; when available, specific for bone turnover |
| P1NP | Marker of bone formation; high in high turnover | Research; emerging use in clinical practice |
| CTX | Marker of bone resorption | Less used in CKD; more in osteoporosis research |
| FGF-23 | Markedly elevated in CKD; reflects phosphate burden | Research marker; not routinely ordered; prognostic for CV events |
Trends matter more than absolute values. A PTH rising from 100 to 400 pg/mL over months indicates worsening SHPT and need for intervention, even if <500. Conversely, stable PTH at 200 in a patient with good phosphate control may not need adjustment.
FGF-23 is markedly elevated in CKD and associated with:
Mechanism: Loss of Klotho (kidney is primary source) → reduced FGF-23 signaling → unchecked phosphate retention and PTH activation.